


## hCA/Wnt/ $\beta$ -catenin-IN-1

Cat. No.:	HY-155391
CAS No.:	3032826-63-1
Molecular Formula:	C <sub>26</sub> H <sub>24</sub> N <sub>2</sub> O <sub>6</sub> S
Molecular Weight:	492.54
Target:	Carbonic Anhydrase; P-glycoprotein; Wnt; $\beta$ -catenin
Pathway:	Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel; Stem Cell/Wnt
Storage:	Powder    -20°C    3 years In solvent   -80°C    6 months -20°C    1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (253.79 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.0303 mL	10.1515 mL	20.3029 mL
	5 mM		0.4061 mL	2.0303 mL	4.0606 mL
	10 mM		0.2030 mL	1.0151 mL	2.0303 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

hCA/Wnt/ $\beta$ -catenin-IN-1 (Compd 15) is an inhibitor of hCA ( $K_i$ : 33.6, 24.1, 6.8 nM for hCA II, hCA IX, hCA XII). hCA/Wnt/ $\beta$ -catenin-IN-1 reduces P-gp activity. hCA/Wnt/ $\beta$ -catenin-IN-1 also inhibits Wnt/ $\beta$ -catenin signaling pathway. hCA/Wnt/ $\beta$ -catenin-IN-1 inhibits cancer cell viability, including the NCI/ADR-RES DOX-resistant cell line<sup>[1]</sup>.

### REFERENCES

[1]. Masci D, et al. 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1H-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/ $\beta$ -Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells. J Med Chem. 2023 Oct 30.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA